TGA greenlights hep C drug

The TGA has approved Sofosbuvir, a once-a-day oral antiviral that could cure most hepatitis C cases.

The nucleotide analogue polymerase inhibitor works across all genotypes of hepatitis C and can cure up to 90% of patients with certain genotypes of the virus, according to Gilead, which markets the drug under the brand name Sovaldi.

However, the drug is expensive and getting a PBS